Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16356146 | 1.00 | KMT2A (0.38) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16324638 | 0.82 | CYP3A4 (0.53) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16324639 | 0.82 | CYP3A4 (0.53) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16321961 | 0.78 | CYP3A4 (0.41) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16321957 | 0.78 | CYP3A4 (0.41) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL21667379 | 0.77 | KMT2A (0.57) | KMT2AGAAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16341720 | 0.76 | HTT (0.31) | KMT2AMAPTSMN1; SMN2HSD17B10TSHR | |
| SCHEMBL16341721 | 0.76 | HTT (0.31) | KMT2AMAPTSMN1; SMN2HSD17B10TSHR | |
| SCHEMBL16321200 | 0.76 | SMN1; SMN2 (0.63) | KMT2AMAPTSMN1; SMN2HSD17B10TSHR | |
| SCHEMBL16321199 | 0.76 | SMN1; SMN2 (0.63) | KMT2AMAPTSMN1; SMN2HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3702352-A1 | PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | KMT2A 3990/4885GAA 1172/4885MAPT 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.